Cenduit Announces Upgraded Patient Reminders Tool
Upgraded tool improves sponsor-patient communication with two-way messaging dashboard
Research Triangle Park, NC â May 25, 2016 â Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, today announced the launch of its upgraded Patient RemindersTM tool. Designed to improve patient compliance and engagement without placing additional burdens on sites or sponsors, the expanded features include a two-way messaging dashboard and a mobile app available for iOS and Android devices. As the world’s largest IRT specialist, Cenduit is leveraging the company’s deep expertise in clinical domain to improve sponsor-patient interactions throughout the duration of the trial. Using personalized messaging to remind patients of any scheduled appointments and necessary preparations for their clinical visit, Patient Reminders effectively improves patient compliance and retention in clinical trials, saving sponsors on costs resulting from patient dropout and noncompliance. The tool can be easily integrated with existing Interactive Response Technology (IRT) systems or as a standalone service, simplifying patient communications throughout the trial. “Patient compliance is key to the success of any clinical trial. With our Patient Reminders tool, sponsors can have more control of their clinical trials and reduce patient dropout, which saves them time and money while increasing the quality of a trial’s endpoint data,” said Chris Dailey, global head of technology, Cenduit. “With new features, the upgraded tool gives sponsors a simple means to keep patients engaged in their trials by communicating in real time through the two-way messaging dashboard.” The two-way messaging dashboard gives site users and sponsors a consolidated view of all interactions with patients. The dashboard allows for the monitoring of any reminders sent to patients, as well as their responses, to ensure the patients remain on track for any scheduled visits and medications. Patients can also now send their responses to sponsors with an additional layer of security and privacy through the convenience of a mobile app, available for download on iOS and Android devices. To learn more about Cenduit’s enhanced patient reminder tool, visit
http://www.cenduit.com/patient-reminders
.
About Cenduit
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration. Cenduit has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at
www.cenduit.com
and on Twitter at
@CenduitLLC
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
